The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53

Area of Science:

• Cell Biology
• Cancer Research
• Molecular Oncology

Background:

• Stathmin/oncoprotein18 is a microtubule-destabilizing protein.
• Depletion of stathmin in cancer cells can induce G2 cell cycle delay and apoptosis.
• These effects are observed specifically in cells with low p53 levels.

Purpose of the Study:

• To investigate the pathways activated by stathmin depletion that lead to cell cycle delay.
• To understand the role of microtubules in the stathmin depletion-induced G2 delay.
• To elucidate the interplay between stathmin, p53, and cell cycle regulation.

Main Methods:

• Depletion of stathmin protein in cancer cell lines.
• Assessment of microtubule (MT) stability using markers like acetylated α-tubulin and centrosomal MT nucleation rates.
• Treatment with MT-depolymerizing drugs (nocodazole, vinblastine) and MT-stabilizing drug (paclitaxel).
• Cell cycle analysis using markers like TPX2 and phosphorylated CDK1.
• Live cell imaging to monitor cell cycle progression.

Main Results:

• Stathmin depletion enhanced MT stability, particularly in p53-deficient cells.
• MT depolymerization abrogated the G2 delay, indicating MTs are required for this delay.
• Live imaging revealed stathmin depletion specifically prolonged the G2 phase, not mitosis.
• MT stabilization alone (paclitaxel) did not induce a G2 delay.

Conclusions:

• Microtubule integrity is essential for the G2 cell cycle delay induced by stathmin depletion.
• The G2 delay is dependent on the interplay between stathmin levels, p53 status, and microtubule dynamics.
• Stathmin depletion activates a pathway requiring functional microtubules to extend the G2 phase, independent of mitotic duration.